<DOC>
	<DOCNO>NCT00696878</DOCNO>
	<brief_summary>The objective trial ass non-immunogenicity safety corifollitropin alfa ( also know Org 36286 , SCH 900962 MK-8962 ) participant undergo repeat COS cycle use multiple dose GnRH antagonist protocol .</brief_summary>
	<brief_title>Corifollitropin Alfa Participants Undergoing Repeated Controlled Ovarian Stimulation ( COS ) Cycles Using Multiple Dose Gonadatropin Releasing Hormone ( GnRH ) Antagonist Protocol ( Study 38825 ) ( P05714 )</brief_title>
	<detailed_description>This trial design open-label , uncontrolled , repeated cycle trial ass non-immunogenicity safety corifollitropin alfa participant undergo repeat COS cycle vitro fertilization ( IVF ) intracytoplasmic sperm injection ( ICSI ) use multiple dose GnRH antagonist protocol . The trial period per participant cover 1 , 2 3 COS treatment cycle three ( in-between two stimulation cycle ) Frozen-Thawed Embryo Transfer ( FTET ) cycle follow either first two treatment cycle . In stimulation cycle , participant receive single injection corifollitropin alfa one week later , treatment continue daily dose FSH-containing preparation day ( rec ) hCG administration final oocyte maturation . Assessment anti-corifollitropin alfa antibody local tolerance corifollitropin alfa injection important safety endpoint trial .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Females couple indication COS IVF ICSI ; &gt; =18 &lt; =39 year age time sign informed consent ; Body weight &gt; 60 kg body mass index ( BMI ) &gt; =18 &lt; =29 kg/m^2 ; Normal menstrual cycle length : 2435 day ; Availability ejaculatory sperm ( use donate and/or cryopreserved sperm allow ) ; Willing able sign inform consent . History current ( treat ) endocrine abnormality ; History ovarian hyperresponse history ovarian hyperstimulation syndrome ( OHSS ) ; History current polycystic ovary syndrome ( PCOS ) ; More 20 basal antral follicle ( size : &lt; 11 mm , ovary combine ) measure USS early follicular phase ( menstrual cycle day 25 ) ; Less 2 ovary ovarian abnormality , include endometrioma &gt; 10 mm ( visible USS ) ; Presence unilateral bilateral hydrosalpinx ( visible USS ) ; More three unsuccessful COS cycle since last establish ongoing pregnancy ( applicable ) ; History non low ovarian response FSH/human menopausal gonadotrophin ( hMG ) treatment ; FSH &gt; 12 IU/L luteinizing hormone ( LH ) &gt; 12 IU/L measure local laboratory ( sample take early follicular phase : menstrual cycle day 25 ) ; Any clinically relevant abnormal laboratory value base sample take screening phase , include abnormal cervical smear ( Papanicolaou [ PAP ] &gt; =III , cervical intraepithelial neoplasia [ CIN ] &gt; =1 ) ; Contraindications use gonadotropin ( e.g . tumor , pregnancy/lactation , undiagnosed vaginal bleeding , hypersensitivity , ovarian cyst ) GnRH antagonist ( e.g . hypersensitivity , pregnancy/lactation ) ; Recent history current epilepsy , human immunodeficiency virus ( HIV ) infection , thrombophilia , diabetes cardiovascular , gastrointestinal , hepatic , renal , pulmonary disease ; Abnormal karyotyping participant partner ( karyotyping perform ) ; History presence alcohol drug abuse within 12 month prior sign informed consent ; Previous use corifollitropin alfa ; Use hormonal preparation within 1 month prior screen ; Administration investigational drug within three month prior sign inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Infertility</keyword>
	<keyword>Pharmacological effect drug</keyword>
	<keyword>Hormones , Hormone Substitutes Hormone Antagonists</keyword>
	<keyword>Pharmacological Actions</keyword>
	<keyword>Multi-center</keyword>
</DOC>